| Old Articles: <Older 3081-3090 Newer> |
|---|
 |
Managed Care
August 2006
Lola Butcher |
For Kansas, It's All In the (ID) Cards Inaccurate data on patient ID cards is the top headache that a Kansas commission has decided to address using improved information technology.   |
Managed Care
August 2006
Thomas Morrow |
New Injectable Medication Effective Against Wet AMD Age-related macular degeneration is the most common cause of blindness in people over age 55. This market will expand rapidly. Managed care should remain informed and start to manage this area. |
The Motley Fool
September 1, 2006
Brian Lawler |
Bristol-Myers and Sanofi Get Apotex to Stop A temporary injunction against generic drug manufacturer Apotex over patents involving Plavix means big news for all the companies involved. |
IEEE Spectrum
September 2006
Kieron Murphy |
Q&A With: Michael Weiner We talk with the CEO of Biophan Technologies, a cutting-edge developer of biomedical device components about the industry, how his company fits into the med-tech market and how engineering contributes to improving quality of life. |
The Motley Fool
August 30, 2006
Brian Gorman |
Mylan's Biogeneric Play The generic drugmaker buys an Indian firm to strengthen its long-term prospects. Investors, take note. |
The Motley Fool
August 29, 2006
Brian Lawler |
More Good News for Rituxan Genentech and Biogen Idec's drug shows positive results against multiple sclerosis. Investors, take note. |
BusinessWeek
September 4, 2006
Heather Green |
It Takes A Web Village Private online communities are providing special insights into customers' needs. |
The Motley Fool
August 25, 2006
Brian Gorman |
California's Drug Demands As the pressure grows on drugmakers from legislation, growth and consolidation in the outsourcing business seem likely. |
The Motley Fool
August 23, 2006
S.J. Caplan |
Wyeth Feeling Happy The FDA cancels a meeting related to the market application for Wyeth's experimental antidepressant. Investors, take note. |
The Motley Fool
August 22, 2006
Brian Lawler |
Sticking With Myriad Genetics The potential for growth in one division offsets the risk in its trials for an Alzheimer's drug. For less risk-adverse investors, the 5% pullback in Myriad's shares Tuesday might offer a great chance to invest in this well-run company. |
| <Older 3081-3090 Newer> Return to current articles. |
